



# BERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES

**Bergen, Norway, 8 March 2021** – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that Richard Godfrey, CEO of BerGenBio, will be presenting at the following virtual conferences:

## **H.C. Wainwright Global Life Sciences Conference**

**Date:** 9-10 March 2021

*Presentation available during the conference*

[Registration for attendees](#)

## **Sachs European Life Sciences CEO Forum**

**Date:** 10-11 March 2021

*Live presentation, Thursday 11 March at 13:10 CET*

[Registration for attendees](#)

## **Carnegie Nordic Virtual Healthcare Seminar**

**Date:** 12 March 2021

*Live presentation, Friday 12 March at 11.15 CET*

Presentations will be made available on the Company website in the Presentations section on the day of the respective events:

[www.bergenbio.com/investors/presentations/](http://www.bergenbio.com/investors/presentations/)

– END –

## **About BerGenBio ASA**

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to identify patient populations most likely to benefit from AXL inhibition: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit [www.bergenbio.com](http://www.bergenbio.com)

## **Contacts**

[ir@bergenbio.com](mailto:ir@bergenbio.com)

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA  
[rune.skeie@bergenbio.com](mailto:rune.skeie@bergenbio.com)  
+47 917 86 513

## **International Media Relations**

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications  
[bergenbio@consilium-comms.com](mailto:bergenbio@consilium-comms.com)  
+44 20 3709 5700

## **Media Relations in Norway**

Jan Petter Stiff, Crux Advisers

[stiff@crux.no](mailto:stiff@crux.no)

+47 995 13 891

#### Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

**This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.**